Shift Bioscience - About the company
Shift Bioscience is a seed company based in Cambridge (United Kingdom), founded in 2017 by Daniel Ives. It operates as a Developer of drugs that reprogram mitochondrial (mtDNA) mutations. Shift Bioscience has raised $28.6M in funding from BGF. The company has 241 active competitors, including 92 funded and 47 that have exited. Its top competitors include companies like Nimbus Therapeutics, Regenxbio and Madrigal Pharmaceuticals.
Company Details
Developer of drugs that reprogram mitochondrial (mtDNA) mutations. The company is developing novel drug molecules that can treat diseases where mitochondrial DNA (mtDNA) damage is identified. It has identified small drug agonists able to trigger mitochondrial gene shifting by metabolic reprogramming in specific tissues. The company claims that these molecules can treat age-related diseases such as neurodegenerative diseases or coronary heart disease.
- Website
- shiftbioscience.com
- Social
- Email ID
- *****@shiftbioscience.com
Key Metrics
Founded Year
2017
Location
Cambridge, United Kingdom
Stage
Seed
Total Funding
$28.6M in 7 rounds
Latest Funding Round
Ranked
18th among 241 active competitors
Employee Count
23 as on Sep 30, 2026
Legal entities associated with Shift Bioscience
Shift Bioscience is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
SHIFT BIOSCIENCE LIMITED CIN: 10793871 , United Kingdom, Active | May 29, 2017 | - | 18 (As on Jun 30, 2025) |
Sign up to download Shift Bioscience's company profile
Shift Bioscience's funding and investors
Shift Bioscience has raised a total funding of $28.6M over 7 rounds. Its first funding round was on Apr 11, 2019. Its latest funding round was a Seed round on Oct 16, 2024 for $*****. 4 investors participated in its latest round. Shift Bioscience has 9 institutional investors and 10 angel investors.
Here is the list of recent funding rounds of Shift Bioscience:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 16, 2024 | 1547834 | Seed | 3618914 | 5261838 | 3919753 | 4014534 |
Aug 24, 2022 | 9251875 | Seed | 9842214 | 2832367 | 8191278 | 6925441 |
Jun 11, 2022 | 1427395 | Seed | 7004194 | 9401663 | 7054925 | 9724446 |
Access funding benchmarks and valuations. Sign up today!View details of Shift Bioscience's funding rounds and investors
Shift Bioscience's founders and board of directors
Founder? Claim ProfileThe founders of Shift Bioscience is Daniel Ives. Daniel Ives is the CEO of Shift Bioscience.
Here are the details of Shift Bioscience's key team members:
- Daniel Ives: Founder & CEO of Shift Bioscience.
View details of Shift Bioscience's Founder profiles and Board Members
Shift Bioscience's employee count trend
Shift Bioscience has 23 employees as of Sep 26. Here is Shift Bioscience's employee count trend over the years:
Uncover Shift Bioscience's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Shift Bioscience's Competitors and alternates
Top competitors of Shift Bioscience include Nimbus Therapeutics, Regenxbio and Madrigal Pharmaceuticals. Here is the list of Top 10 competitors of Shift Bioscience, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
2nd | Regenxbio 2008, Rockville (United States), Public | Developer of AAV Gene Therapy for rare genetic diseases | $108M | 67/100 | |
3rd | Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired | Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis | $38.4M | 66/100 | |
4th |  Mammoth 2017, Brisbane (United States), Series D | Provider of molecular diagnostics platform by using CRISPR technology | $271M | 65/100 | |
5th | Developer of a novel treatment for metabolic diseases | $138M | 64/100 | ||
6th |  NewLimit 2022, San Francisco (United States), Series C | Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension | $682M | 63/100 | |
7th | Intercept Pharmaceuticals 2002, New York City (United States), Acquired | Developer of therapeutics to treat progressive non-viral liver diseases | $121M | 63/100 | |
8th | _1551769784760.png?devicePixelRatio=2&height=30&width=30){kind=logo} Rejuvenate Bio 2018, San Diego (United States), Series A | Developer of gene therapies for treating chronic and age-related diseases | $34M | 63/100 | |
9th | Lyra Therapeutics 2005, Watertown (United States), Public | Biotechnology firm innovating localized therapies for chronic rhinosinusitis (CRS) | $110M | 61/100 | |
10th |  Mirum Pharmaceuticals 2018, Menlo Park (United States), Public | Developer of small molecule based therapeutics to treat rare diseases | $120M | 61/100 | |
18th | Shift Bioscience 2017, Cambridge (United Kingdom), Seed | Developer of drugs that reprogram mitochondrial (mtDNA) mutations | $28.6M | 61/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Shift Bioscience's competitors? Click here to see the top ones
Shift Bioscience's Investments and acquisitions
Shift Bioscience has made no investments or acquisitions yet.
Reports related to Shift Bioscience
Here is the latest report on Shift Bioscience's sector:
News related to Shift Bioscience
Media has covered Shift Bioscience for 1 event in last 1 year, It was about company updates.
•
Shift Bioscience Publishes Improved Metric Calibration Framework for Robust Genetic Perturbation Modeling Using AI Virtual CellsBusiness Wire•Nov 11, 2025•Shift Bioscience
•
Shift Bioscience makes double appointment to support long-term strategy for cell rejuvenation therapeuticsInsider Media•May 21, 2025•Shift Bioscience
•
Shift Bioscience adds experts Lord Prior & Sir Kouzarides to advance cell rejuvenation therapies.
Business Wire•May 20, 2025•Shift Bioscience
•
Shift Bioscience Announces Key Appointments to Advance Rejuvenation Therapeutics PipelineBusiness Wire•Mar 12, 2025•Shift Bioscience
•
Shift Bioscience Establishes North American Facilities To Expand Capabilities Of Ai-powered Virtual Cell TechnologyFinancial Post•Feb 18, 2025•Shift Bioscience
•
£12.5m funding for biotechnology firm wins deal of the monthInsider Media•Nov 29, 2024•Shift Bioscience, BGF, F-Prime Capital, Kindred Capital
•
Shift Bioscience: $16 Million (Seed) Raised To Use GenAI For Reversing Aging ProcessesPulse 2.0•Nov 03, 2024•Shift Bioscience, BGF, F-Prime Capital, Kindred Capital
•
Shift Bioscience raises $16 M to advance cell simulation AI platformNews Medical•Oct 16, 2024•Shift Bioscience, BGF, F-Prime Capital, Kindred Capital and 1 other
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Shift Bioscience
Explore our recently published companies
- Job Impulse Portugal RH - Portugal based, 2006 founded, Unfunded company
- Dobuy, Data - United Arab Emirates based, 2024 founded, Unfunded company
- Karosseriewerke Weinsberg - Bretzfeld based, Unfunded company
- Recruitment Giant - Nairobi based, 2018 founded, Unfunded company
- SRIK Consulting - India based, 2015 founded, Unfunded company
- Meysot - Leon based, 1951 founded, Unfunded company
